NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000,...

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Significant advancements in cancer therapy have emerged over the past two years.
• These include novel therapeutic strategies, molecular targets, and chemical compounds.

Purpose of the Study:

• To review and discuss recent progress in anticancer drug and prodrug design.
• To highlight new strategies, targets, and compounds in cancer therapy R&D.

Main Methods:

• Focus on new strategies: gene therapy, drug delivery, drug targeting, and prodrug design.
• Identification of new molecular targets: kinases, histone deacetylases, proteasomes, and hypoxic factors.
• Review of improved compounds in clinical trials: tubulin agents, bioreductive agents, and kinase inhibitors.

Main Results:

• Development of innovative approaches in gene therapy and targeted drug delivery.
• Definition of novel targets such as kinases and hypoxic factors for therapeutic intervention.
• Progress in clinical trials for advanced anticancer agents including angiogenesis inhibitors and cyclin-dependent kinase inhibitors.
• Emphasis on chemoprevention and structure-activity relationships to expedite drug development.

Conclusions:

• The field of oncology is rapidly advancing with new therapeutic strategies and drug candidates.
• Continued research into novel targets and improved drug design is crucial for developing next-generation cancer treatments.
• Structure-activity relationship studies are vital for accelerating the discovery of more effective anticancer drugs.